Case Report

Aplasia cutis congenita: Two case reports and discussion of the literature

Blionas Alexandros, Giakoumettis Dimitrios¹, Antoniades Elias², Drosos Evangelos¹, Mitsios Andreas³, Plakas Sotirios⁴, Sfakianos Georgios³, Themistocleous S. Marios³

Department of Neurosurgery, Asklepieion Hospital of Voula, Voula, ¹Department of Neurosurgery, University of Athens Medical School, “Evangelismos” General Hospital, ²Department of Neurosurgery, Children’s Hospital “Agia Sofia”, Athens, ³Department of Neurosurgery, University of Thessaloniki Medical School, “AHEPA” University Hospital, Thessaloniki, Greece, ⁴Department of Neurosurgery, Children’s Hospital “Agia Sofia”, Athens, ⁵Department of Neurosurgery, University of Thessaloniki Medical School, “AHEPA” University Hospital, Thessaloniki, Greece, ⁶Department of Neurosurgery, Children’s Hospital “Agia Sofia”, Athens, ⁷Department of Neurosurgery, University of Thessaloniki Medical School, “AHEPA” University Hospital, Thessaloniki, Greece

E-mail: *Blionas Alexandros - ablionas@gmail.com; Giakoumettis Dimitrios - dgiakoumettis@gmail.com; Antoniades Elias - eliasantoniad@yahoo.gr; Drosos Evangelos - drosose@gmail.com; Mitsios Andreas - ajmitsios@gmail.com; Plakas Sotirios - sotirisplakas@hotmail.com; Sfakianos Georgios - gsfakianos@gmail.com; Themistocleous S. Marios - mthemistocleous@gmail.com
*Corresponding author

Received: 20 May 17  Accepted: 23 August 17  Published: 09 November 17

Abstract

Background: Aplasia cutis congenita (ACC) is a part of a heterogeneous group of conditions characterized by the congenital absence of epidermis, dermis, and, in some cases, subcutaneous tissues or bone usually involving the scalp vertex. There is an estimated incidence of 3 in 10,000 births resulting in a total number of 500 reported cases to date. The lesions may occur on every body surface although localized scalp lesions form the most frequent pattern (70%). Complete aplasia involving bone defects occurs in approximately 20% of cases. ACC can occur as an isolated defect or can be associated with a number of other congenital anomalies such as limb anomalies or embryologic malformations. In patients with large scalp and skull defects, there is increased risk of infection and bleeding along with increased mortality and therefore prompt and effective management is advised.

Case Description: We describe two cases of ACC, involving a 4 × 3 cm defect managed conservatively and a larger 10 × 5 cm defect managed surgically with the use of a temporo-occipital scalp flap. Both cases had an excellent outcome.

Conclusions: Multiple treatment regimens exist for ACC, but there is no consensus on treatment strategies. Conservative treatment has been described and advocated, but many authors have emphasized the disadvantages of this treatment modality. Decision between conservative and surgical management must be individualized according to lesion size and location.

Key Words: Aplasia cutis congenita, congenital anomalies, cranial reconstruction, scalp reconstruction

Access this article online
Website: www.surgicalneurologyint.com
DOI: 10.4103/sni.sni_188_17
Quick Response Code:

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Alexandros B, Dimitrios G, Elias A, Evangelos D, Andreas M, Sotirios P, et al. Aplasia cutis congenita: Two case reports and discussion of the literature. Surg Neurol Int 2017;8:273. http://surgicalneurologyint.com/Aplasia cutis congenita: Two-case-reports-and-discussion-of-the-literature/
INTRODUCTION

Aplasia cutis congenita (ACC) is a heterogenous group of disorders reported historically by Cordon in 1767, and characterized by the absence of epidermis, dermis, and occasionally subcutaneous tissues or even bone tissue, involving multiple possible body locations. The most common lesion location is the scalp (70%);[17,41,41] however, any skin site can be affected and there is also a rare universally fatal subcategory affecting the majority of the dermis.[31,59] In 1986, a classification system was devised by Frieden consisting of nine main ACC types based on the number, the location of the lesions, and the presence or absence of associated deformities.[13] which is shown in Table 1.[7]

ACC holds an estimated incidence of about 3 in 10,000 births and there has been a total of approximately 500 reported cases in the literature.[32] The strongest risk factor reported in the literature is the antithyroid drug Methimazole,[18,20,21,39,40,55] which according to Frieden classification, can be categorized into type 8 ACC. However, cases of ACC are extremely limited due to the very low incidence and, therefore, it is not possible to derive completely accurate epidemiological data.

Table 1: Frieden classification of ACC types

| Type | Characteristics |
|------|-----------------|
| 1    | ACC located on the scalp with no other anomalies whatsoever |
| 2    | ACC located on the scalp but with concomitant limb anomalies such as: |
|      | Limb malformations (Adams-Oliver syndrome) |
|      | Hypoplasia or aplasia of the distal phalanges |
|      | Vascular malformations, fibromas, nipple and hair abnormalities |
| 3    | ACC of the scalp along with epidermal nevi, neurological and ophthalmic abnormalities: (such as seizures, mental impairment, corneal and eyelid lesions) |
| 4    | ACC accompanied by embryologic deformities: such as omphalolele, leptomeningeal angiomatosis, cranial stenosis, porencephaly, meningomyelocele, spinal dysraphism, or gastrochisis |
| 5    | ACC along with fetus papyraceous, placental infarct; Extensive ACC of the trunk or limbs |
| 6    | ACC and epidermolysis bullosa involving the lower extremities |
| 7    | ACC with no epidermolysis bullosa involving the extremities |
| 8    | Teratogen associated ACC: herpes simplex and varicella-zoster virus intrauterine infections, and drugs during pregnancy such as methimazole or carbimazole |
| 9    | ACC accompanied by congenital malformations such as: |
|      | Patau syndrome (Trisomy 13), Wolf-Hirschhorn (4p deletion), Setleis syndrome |
|      | Johanson-Blizzard syndrome, Goltz syndrome, ADAM complex, Kabuki syndrome |
|      | Dellman syndrome, Finlay-Mark syndrome, XY gonadal dysgenesis |

Pathophysiology of ACC is not well studied and its exact pathogenesis is unknown.[11,22,30,35,36] However, there are multiple factors that are probably contributing to the development of ACC according to the literature:

- Chromosomal abnormalities,[6,31] especially BMS1[29]; a recent study has also implicated the UBA2 gene
- Trauma[26,53]
- Amniotic irregularities[7]
- Intrauterine complications, such as vascular accidents or infection[7,9,15,36]
- Thrombosis, vascular lesions[7,9,15]
- Teratogens: such as misoprostol, benzodiazepines, valproic acid, cocaine, methotrexate, ACE inhibitors, methimazol[18,33,39,40,44,50].

The main pathophysiologic hypothesis about ACC is that the mechanism behind it lies in tension-induced disruption of the overlying skin occurring at 10–15 weeks of gestation when rapid brain growth occurs along with hair direction and patterning.[51] Another less prevalent model is that premature amniotic membrane rupture and amniotic band formation might be the cause of ACC.[7]

CASE DESCRIPTIONS

The following cases are categorized as group 1 ACC and involve patients with multiple scalp bullous lesions, with both skin and bone layer defects. We will describe both cases and discuss presentation, prognosis, and management strategies.

First case

Our first patient was a 3500 g white boy of 37 weeks of gestation. Pregnancy, labor, and delivery were without any mishaps. From the obstetrical record, we were informed that the mother was treated for hypothyroidism with T4 and also with Ritodrine (Utopar®) due to uterine contractions. No abnormal family history was reported. At birth, the boy was found to have three sizable bullae on his scalp. There was a large round-shaped occipital defect at the vertex with dimensions of 4 × 3 cm and two lesser ones at the frontal vertex with dimensions of 1 × 2 and 1 × 1 cm [Figures 1 and 2]. The defects included both scalp and skin layers and were confirmed by ultrasound and computed tomography (CT) scan examinations. The CT scan also revealed suture diastasis with thinning and hypoplasia of the fronto-parietal bones [Figure 3]. A thin membrane was covering the defect in immediate proximity to the superior sagittal sinus. During the following days, a dark dry eschar developed covering the lesion. A conservative management strategy was adapted due to relatively small size of the lesions. The wound was vigorously cleaned daily initially with betadine solution and furthermore with fucidin gauze and sterile dressings. The eschar became well demarcated shortly and the healing process...
was mostly satisfying. Intravenous chemoprophylaxis with third-generation Cephalosporin (Cefotaxime®) and Teicoplanin (Targocid®) was concomitantly administered. Complete wound closure occurred at 42 days.

Second case

Our second patient was a 3660 g white boy of 42 weeks of gestation. Pregnancy, labor, and delivery were without any mishaps. The obstetrical record included history of induced delivery. The medical record revealed a family history of ACC involving the patient’s father and siblings. At birth, the patient had an extensive round-shaped hemorrhagic bullae with dimensions of 10 × 5 cm above the fronto-occipital regions of the scalp [Figures 4 and 5]. The defect included scalp and skin layers, which was confirmed by ultrasound and magnetic resonance imaging (MRI) scan examinations [Figure 6]. The MRI scan revealed a complete loss of continuity of the dermal and subcutaneous tissues [Figure 6]. Yet again, a thin membrane covered the defect in immediate proximity to the superior sagittal sinus. In contrast to the first case, in this case surgical treatment was adapted due to the increased size of the lesion, along with the proximity to the superior sagittal sinus. The defect was covered by using a single temporo-occipital scalp flap. Chemoprophylaxis was given with intravenous injections of Ceftazidime (Solvetan®) and Teicoplanin (Targocid®). During the postoperative period, blood examinations showed increased inflammatory indexes and blood cultures were found positive for *Enterobacter cloacae*, and therefore antibiotic treatment was modified to Meropenem (Meronem®) and Vancomycin (Voncon®). Unfortunately, the infant developed septic shock influencing coagulation factors VII and IX, and thus was promptly provided with units of fresh frozen plasma. Defected areas were treated with betadine scrub and sterile gauze dressing. Following daily local treatment, the wound gradually epithelialized, and complete epithelialization was achieved at 37 days.

DISCUSSION

In the majority of cases (70%) ACC manifests as a solitary defect of the scalp, but occasionally it may present with multiple lesions such as in our first case. Although lesions
are noninflammatory and well demarcated, there is great controversy concerning treatment of ACC and there has been a great scientific interest due to the extremely high mortality figures that range from 20 to 55%. High mortality/morbidity rates are a result of sagittal sinus bleeding, secondary local infection, meningitis, sagittal sinus thrombosis, or the direct result of other serious congenital defects that are associated with ACC. On examining both the presented cases, it was observed that both had lesions in very close proximity to the superior sagittal sinus; therefore, the imminent risk of infection and bleeding is apparent. Bleeding of the superior sagittal sinus is the most life-threatening complication of ACC with 36% mortality. This fatal complication occurs between 1 and 3 months of age, has been shown to be more frequent with lesions involving a larger portion of the superior sagittal sinus, and is probably the cause of superior sagittal sinus exposure and insufficient protection. It is important to prevent such fatal complications through prompt and effective ACC management.

The management of scalp ACC is controversial. Treatment may be either conservative or operative, and there is no consensus or guidelines on treatment strategy. Choosing between conservative and operative modalities is challenging and should be individualized. Lesion size is the only universally accepted criterion with larger lesions favoring the surgical approach. Additionally, lesion location plays an important role, with lesions above critical areas, especially with sagittal sinus compromise favoring a surgical approach due to increased bleeding and infection risk.

Conservative management consists of regular wound cleansing and application of dressings along with the use of systemic antibiotics. This includes physiological saline, continuous saline drips, betadine solution, bacitracin ointment, and silver sulfadiazine dressings, which are utilized in order to preserve moisture, prevent desiccation, and allow spontaneous epithelialization to occur. There are multiple reports of specialized adherent wound dressings that are thought to offer increased wound healing rates as well as recent reports of novel dressing materials such as fatty gauzes. However, none of the more specialized dressing materials have proven to be significantly superior, and therefore, it is accepted to treat ACC with standard traditional wound care. Although conservative treatment has traditionally been the default strategy for normal and small-sized lesions, lately there have been reports of extensive ACC lesions managed through the conservative route with excellent healing results and this shows a tendency of recent literature in favor of the conservative approach. In addition, there have been reports of even more specialized conservative treatment techniques such as the use of autologous cultured fibroblasts and keratinocytes or the application of fibroblast growth factors that accelerate wound healing, a modality which might represent the future of ACC treatment drastically decreasing the number of surgically managed cases.

Surgical management, on the contrary, includes various procedures. Standard surgical care includes primary wound closure, skin grafting (autologous or allografts), local scalp flaps with or without tissue expansion, free flaps, muscle flaps, full-thickness or split-thickness skin grafts, and cranial vault reconstruction using bone grafts. Specialized surgical techniques such as utilizing bipedicle opposing local flaps, rotational flaps, or L-shaped flaps have been used with satisfying results. However, wound repair through a single, large scalp flap seems adequate and effective for the majority of ACC lesions, offering adequate wound closure and protection of the sensitive underlying structures. Closure of the associated skull defect is usually achieved through the use of artificial bone grafts, which should be designed according to current bone defect size, although the use of autologous bone grafts has been described. Bone defects, according to the literature, can self-regenerate with an impressive speed; however, many authors advise to repair skin defects and
skull defects concomitantly for optimal results,\(^{[14]}\) or in a delayed cranioplasty operation. In conclusion, the exact surgical technique must be tailored according to each individual patient and lesion, as well as the surgeon's personal preference and expertise.\(^{[16]}\) Surgery for ACC is accompanied by the usual complications of every surgical operation, and consists mainly of intraoperative hemorrhage and postoperative infections. These complications are rare, but can be effectively managed. Since ACC mortality is particularly high especially for larger lesions due to similar complications involving both life-threatening hemorrhage and infection, postoperative complications should not be considered as a discouraging factor when managing a patient with an extended ACC lesion.\(^{[11]}\)

**CONCLUSION**

In conclusion, we strongly believe that a conservative approach minimizes complications, avoids unwanted operative sequelae, and takes full advantage of the innate rapid regeneration ability of the newborn.\(^{[17]}\) Therefore, whenever the conservative approach seems feasible, it is strongly advised to initially adapt it and save the surgical approach in cases of treatment failure.\(^{[11]}\) In the near future, even more technologies are available to enable wound healing and wound closure, such as fibroblast growth factors and cultured skin, possibly even rendering surgical management obsolete. Throughout the literature, there are reports of extremely large defects treated conservatively with impressive results,\(^{[14]}\) however, there are no reports of surgical management for lesions of size \(<30 \text{ cm}^2\).\(^{[23]}\) Present publications generally illustrate that conservative management is preferable, and surgical management is generally considered, but not always utilized, for lesions of size \(>30 \text{ cm}^2\).

In our specific cases, we utilized a conservative approach in Case 1, which involved a smaller defect \((1 \times 2 \text{ cm})\), whereas for the larger defect of Case 2 \((10 \times 5 \text{ cm})\), a surgical approach with the application of a single scalp flap was utilized. Results were satisfying in both cases, with complete wound closure. Taking into account both our own experience and the literature, we strongly believe that utilizing a size threshold for deciding between conservative or surgical approach along with meticulous sterile dressings and wound care is the optimal management strategy for ACC. The optimal size threshold and specific treatment guidelines remain yet to be determined. The literature complete lacks any precise guidelines or suggestions on the subject and further research is required. Therefore, it must be noted that due to the lack of treatment algorithms and guidelines on ACC management and the need for individualized treatment decisions, it is important for such cases to be managed in centers specialized in pediatric neurosurgery with sufficient experience and expertise.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Abbott R, Cutting CB, Wisoff JH, Thorne CH, Epstein FJ. Aplasia cutis congenita of the scalp: Issues in its management. Pediatr Neurosurg 1991-1992;17:182-4.
2. Atalla MF, el-Sayed AM. Scalp aplasia cutis congenita: Closure by the L-shaped flap. Childs Nerv Syst 1992;8:287-8.
3. Azad S, Falder S, Harrison J, Graham K. An adherent dressing for aplasia cutis congenita. Br J Plast Surg 2005;58:1159-61.
4. Ba̜şçı̜ṛzi̜ Y1, Ba̜şçı̜roẓlu̜̣ ̣C̣, Ṣa̜ri̜̣ A̜, Demirkan F. Aplasia cutis congenita of the scalp and calvarium. J Craniofac Surg 2007;18:427-9.
5. Beekmans SJA, Haumann TJ, Vandertop WP, Mulder JW. [Aplasia cutis congenita in 4 infants]. Ned Tijdschr Geneeskd 2002;146:1842-5.
6. Bharti G, Groves L, David LR, Sanger C, Argenta LC. Aplasia Cutis Congenita. J Craniofac Surg 2011;22:159-65.
7. Brezinszki P, Pinteala T, Chiriac AE, Foia L, Chiriac A. Aplasia cutis congenita of the scalp—what are the steps to be followed? Case report and review of the literature. An Bras Dermatol 2015;90:100-3.
8. Caksen H, Kurtoglu S. Our experience with aplasia cutis congenita. J Dermatol Surg 2002;29:376-9.
9. Choi MSS, Choi JH, Ki SH, Jun YH. Aplasia cutis congenita associated with aplasia of the superficial temporal artery, J Craniofac Surg 2016;27:1065-7.
10. Donati V, Arena S, Capilli G, Carrera G, Ciralli F, Liberatore A. Reparation of a severe case of aplasia cutis congenita with engineered skin. Biol Neonate 2001;80:273-6.
11. Duan X, Yang G, Yu D, Yu C, Wang B, Guo Y. Aplasia cutis congenita: A case report and literature review. Exp Ther Med 2015;10:1893-95.
12. Dutra LB, Pereira MD, Krenski TM, Zanon N, Cavaleiros S, Ferreira LM. Aplasia cutis congenita. J Craniofac Surg 2009;20:1288-92.
13. Frieden IJ. Aplasia cutis congenita: A clinical review and proposal for classification. J Am Acad Dermatol 1986;14:646-60.
14. Fröjd V, Maltese G, Kölby L, Tarnow P. Conservative Healing of an 11 × 9-cm Aplasia cutis congenita of the scalp with bone defect. J Neurol Surg Reports 2014;75:e220-3.
15. Guinard D, Lebeau J, Moutet F, Raphael B. Congenital cutaneous aplasia. J Dermatol 2002;29:376-9.
16. Hadad I, Meara JG, Rogers-Vizena CR. A novel local autologous bone graft donor site after scalp tissue expansion in aplasia cutis congenita. J Craniofac Surg 2016;27:904-7.
17. Harvey G, Solanki NS, Anderson PJ, Carney B, Snell BJ. Management of aplasia cutis congenita of the scalp. J Craniofac Surg 2012;23:1662-4.
18. Iwayama H, Hosono H, Yamamoto H, Oshiro M, Ueda N. Aplasia cutis congenita with skull defect in a monozygotic twin after exposure to methimazole in utero. Birth Defects Res. Part A Clin Mol Teratol 2007;79:680-4.
19. Johnson R, Oflah A, Cohen MC. Fatal superior sagittal sinus hemorrhage as a complication of aplasia cutis congenita: A case report and literature review. Forensic Sci Med Pathol 2015;11:243-8.
20. Kalb RE, Grossman ME. The association of aplasia cutis congenita with therapy of maternal thyroid disease. Pediatr Dermatol 1986;3:327-30.
21. Karg E, Bereg E, Gaspar L, Katona M, Turi S. Aplasia cutis congenita after methimazole exposure in utero. Pediatr Dermatol 2004;21:491-4.
22. Kruk-Jeromin J, Janik J, Rykala J. Aplasia cutis congenita of the scalp. Report of 16 cases. Dermatologica 1998;24:549-53.
23. Lahiri A, Nishikawa H. A nonadherent dressing for aplasia cutis congenita. J Plast Reconstr Aesthetic Surg 2006;59:781-2.
24. Leboucq N, Montoya y Martínez P, Montoya-Vigo F, Catan P. Aplasia cutis
congenita of the scalp with large underlying skull defect: A case report. Neurosurgery 1994;34:480-2.
25. Levine SM, Reformat DD, Thorne CH. Cutis aplasia: Perioperative management and case report. Am J Crit Care 2012;21:212-5.
26. Maillet-Declerck M, Vinchon M, Guerreschi P, Pasquesoone L, Dhillenmes P, Duquennoy-Martinot V, et al. Aplasia cutis congenita: Review of 29 cases and proposal of a therapeutic strategy. Eur J Pediatr Surg 2012;23:89-93.
27. Marble M, Guilleln Sacoto MJ, Chikarmane R, Gargiulo D, Juusola J. Missense variant in UBA2 associated with aplasia cutis congenita, duane anomaly, hip dysplasia and other anomalies: A possible new disorder involving the SUMOylation pathway. Am J Med Genet Part A 2017;173:758-61.
28. Marcovici I. Aplasia cutis congenita presenting as vacuum-extractor-related trauma. Int J Gynecol Obstet 2015;139:267-8.
29. Marneros AG. BMS1 is mutated in aplasia cutis congenita. PLoS Genet 2013;9.e1003573.
30. Mesrati H, Amouri M, Chaaben H, Masmoudi A, Boudaya S, Turki H. Aplasia cutis congenita: Report of 22 cases. Int J Dermatol 2015;54:1370-5.
31. Moros Peña M, Labay Matías M, Valle Sánchez F, Valero Adán T, Martín-Calama Valero J, Muñoz Albillos M. [Aplasia cutis congenita in a newborn: Etiopathogenetic review and diagnostic approach]. An Esp Pediatr 2000;52:453-6.
32. O'Neill JK, Carter M, Warr RP. Aplasia cutis congenita. A case of scalp defect repair using two opposing bipedicled local flaps. J Plast Reconstr Aesthetic Surg 2010;63:e242-4.
33. Orgun D, Horiguchi M, Hayashi A, Shimoji K, Arai H, Mizuno H. Conservative treatment of large aplasia cutis congenita of the scalp with bone defect with basic fibroblast growth factor application. J Craniofac Surg 2016;1.1
34. Ploplys EA, Muzaffar AR, Gruss JS, Ellenbogen RG. Early composite cranioplasty in infants with severe aplasia cutis congenita: A report of two cases. Cleft Palate-Craniofacial J 2005;42:442-7.
35. Prager W, Scholz S, Rompel R. Aplasia cutis congenita in two siblings. Eur J Dermatol 2002;12:228-30.
36. Renfree KJ, Dell PC. Distal limb defects and aplasia cutis: Adams–Oliver Syndrome. J Hand Surg Am 2016;41:e207-10.
37. Rhee ST, Colville C, Buchman SR, Muraszko K. Complete osseous regeneration of a large skull defect in a patient with cutis aplasia: A conservative approach. J Craniofac Surg 2002;13:497-500.
38. Ribuffo D, Costantini M, Gullo P, Houseman ND, Taylor GL. Aplasia cutis congenita of the scalp, the skull, and the dura. Scand J Plast Reconstr Surg Hand Surg 2003;37:176-80.
39. Rodriguez-García C, González-Hernández S, Hernández-Martin A, Pérez-Robayna N, Sánchez R, Torrelo A. Aplasia cutis congenita and other anomalies associated with methimazole exposure during pregnancy. Pediatr Dermatol 2011;28:743-5.
40. Sachs C, Tebacher-Alt M, Mark M, Cribier B, Lipsker D. Aplasie cutanée congénitale et antithyroidiens de synthèse au cours de la grossesse: Série de cas et revue de la littérature. Ann Dermatol Venereol 2016;143:423-35.
41. Santos de Oliveira R, Barros Jucit CE, Lopes Lins-Neto A, Aparecida do Carmo Rego M, Farina J, Machado HR. Aplasia cutis congenita of the scalp: Is there a better treatment strategy? Child’s Nerv Syst 2006;22:1072-9.
42. Sargent LA. Aplasia cutis congenita of the scalp. J Pediatr Surg 1990;25:1211-3.
43. Schnabl SM, Horch RE, Ganslandt O, Schroth M, Dragu A, Bach AD, et al. Aplasia cutis congenita – plastic reconstruction of three scalp and skull defects with two opposed scalp rotation flaps and split thickness skin grafting. Neuropediatrics 2009;40:134-6.
44. Shivakumar SK, Dwarakanath S, Swaroop G, Venkataramana NK. Aplasia cutis congenita of the scalp: Therapeutic modalities. Neurol India 2006;54:312-3.
45. Silberstein E, Págalos VA, Landau D, Berezovsky AB, Krieger Y, Shoham Y, et al. Aplasia cutis congenita. Plast Reconstr Surg 2014;134:766e-74e.
46. Šimčí D, Prochič A, Puiszín Ivč N, Željko Penavić J, Tomic T. Aplasia cutis congenita in a newborn child associated with two fetus Papyraceous. Acta Dermatovenerol Croat 2015;23:293-7.
47. Singh M, Bui CJ, St-Hilaire H. Reconstruction of complex aplasia cutis congenita. J Craniofac Surg 2012;23:888-e90.
48. Six EG, Kelly DL. Conservative management of aplasia cutis congenita: Case report. Neurosurgery 1981;8:233-5.
49. Steinbacher J, Rath T, Tzou C-H. Aplasia cutis congenita. Handchirurgie Mikrochirurgie Plast Chir 2016;48:239-43.
50. Suárez O, Lopez-Guztiérez JC, Andrés A, Barrera S, Encinas JL, Luis A, et al. [Aplasia cutis congenita: Surgical treatment and results in 36 cases]. Cir Pediatr 2020;70:151-5.
51. Sugita T, Kouwaki M, Kiyosawa S, Sasada Y, Maeda M, Goto K, et al. A case of systemic aplasia cutis congenita: A newly recognized syndrome? Eur J Pediatr 2008;167:409-13.
52. Thiele RJ, Lanigan MW, McDermott GR. Reconstruction of aplasia cutis congenita of the scalp by split rib cranioplasty and a free latisimus dorsi muscle flap in a nine month old infant. Br J Plast Surg 1995;48:507-10.
53. Trevizo Ortiz L, Ruíz-Maldonado R, Tamayo SL. [Aplasia cutis congenita]. Bol Med Hosp Infant Mex 1978:35:333-42.
54. Vanamo K, Härma M. The Shoelace method in congenital aplasia of the scalp and skull. Eur J Pediatr Surg 2005;15:425-7.
55. Vogt T, Stolz W, Landthalder M. Aplasia cutis congenita after exposure to methimazole: A causal relationship? Br J Dermatol 1995;133:994-6.
56. Wexler A, Harris M, Lesavoy M. Conservative treatment of cutis aplasia. Plast Reconstr Surg 1990;86:1066-71.
57. Yang JY, Yang WG. Large scalp and skull defect in aplasia cutis congenita. Br J Plast Surg 2008;61:619-22.
58. Yilmaz S, Apaydin I, Yenidünya O, Adanali G, Gültan S. Conservative management of aplasia cutis congenita. Dermatol Surg 1997;23:402-3.